Medical Licensing (MD/DO) · Independent exam preparation
EHRA Physician CIED Certification: Clinical Decisions and Device Reasoning Study Guide
Practise pacing indications, CRT and ICD selection, device timing, implant safety and troubleshooting for EHRA physician CIED certification with cases and recall.
By CertMedbry · Updated 20 October 2026
Learn to connect bradycardia mechanisms with pacing indications, select CRT and ICD therapy, interpret device timing and electrograms, and recognise implant complications. This selective guide develops 60 clinical concepts across the CIED specialist syllabus and shared heart-rhythm foundations. The full official learning scope remains the 2024 EHRA Core Curriculum, including shared Table 3 and all 17 CIED chapters in Table 4.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide cover?
This guide covers the EHRA physician CIED pathway, organised by EHRA within ESC. The current programme was named EHRA Cardiac Pacing until 2024. ECDS is historically evidenced as EHRA Certified Cardiac Device Specialist; it does not identify a separate current examination. Allied-professional certification and invasive electrophysiology certification are separate pathways. This professional certification is non-compulsory and non-regulatory; national law determines clinical practice rights.
EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED) · ESC 365 — Doctor Laura Perrotta
How many examination questions contribute to the score?
The programme page checked on 19 October 2026 describes 130 questions in two parts of 65. It states that the 10 least discriminating questions are excluded after statistical analysis, leaving a final score derived from 120 questions. This is post-examination item analysis, not an identified set of pretest questions. The page also describes review and removal of defective items; a separate pretest allocation is not established.
EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
What are the verified duration and item styles?
Each 65-question part lasts three hours, with a one-hour break between parts: six hours of examination time across a seven-hour scheduled examination-and-break period. Official items use clinical scenarios and five options with one best answer, without negative marking. The 20 independent learning questions here each have four options and one best answer.
EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
How is the examination delivered, and is it adaptive?
The current programme page describes online delivery on the candidate's own computer with a human proctor through CYIM/ProctorU. English and French examinations are listed. The verified materials describe a two-part written multiple-choice examination; they do not establish adaptive delivery. Appointment availability and technical requirements belong to the current issuer booking information.
EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
Which curriculum and blueprint apply?
The 2024 updated EHRA Core Curriculum was accepted on 12 September 2024 and published online on 19 September 2024. Shared Table 3 and CIED Table 4 define this pathway's full syllabus; invasive-EP Table 5 is a different specialist syllabus. The programme lists a separate examination-distribution attachment, but its numerical weights, version and examination-specific effective date are unverified. Curriculum knowledge levels are not percentages. This guide, its questions and its cards therefore claim breadth, not proportional blueprint alignment.
2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals · EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
Does passing the written examination complete certification?
The curriculum describes level 1 as the written knowledge assessment and level 2 as recognition of additional practical experience. The physician programme requires both the examination and a successful logbook for full certification. Passing the examination gives access to the logbook process. Practical assessment and OSATS independence levels concern supervised training and competence development; these learning MCQs do not simulate those assessments.
2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals · EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
Is there a fixed published passing percentage?
No fixed passing percentage is established by the supplied current programme information. The curriculum describes modified Angoff standard setting, while the programme page explains that the passing score is linked to minimum required knowledge and that items undergo psychometric analysis. A practice-test percentage should therefore be used to identify learning needs, not converted into an official pass prediction.
EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED) · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
Independent preparation for EHRA Certification in Cardiac Implantable Electronic Devices for Physicians. Clinical recommendations are supported by the cited guidelines, consensus documents and technical manuals; the curriculum establishes subject scope. The four-option drills assess learning and do not predict examination success.
Outline used: 2024 updated EHRA Core Curriculum for physicians and allied professionals; accepted 2024-09-12 and published online 2024-09-19. Current physician programme page consulted 2026-10-13. The workbook label ECDS maps to the historically evidenced EHRA Certified Cardiac Device Specialist designation; it is not a separate current examination. The current official programme is EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED), formerly EHRA Cardiac Pacing until 2024. No separate examination-specific effective date or authenticated current numerical distribution was established. The full official curriculum scope is broader than this selective learning bundle.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Historical perspectives of pacing and CIEDs and their nomenclaturenot stated; examination percentage not verified
1.Which therapeutic functions distinguish pacemakers, ICDs and CRT systems?
CIED terminology describes different diagnostic and therapeutic functions. A pacemaker treats selected bradyarrhythmias through timed stimulation. An ICD detects and treats ventricular tachyarrhythmias, with available pacing functions depending on its design. CRT coordinates ventricular activation to improve selected patients' heart-failure physiology. CRT-P provides resynchronisation pacing, whereas CRT-D adds defibrillator therapy. The decisive distinction is the patient's required treatment functions, rather than assuming every implanted rhythm device provides equivalent protection.
Apply it
A patient needs resynchronisation for symptomatic systolic heart failure but declines defibrillator shocks after an informed discussion. Explain how CRT-P can provide resynchronisation while its capabilities differ from those of CRT-D.
Common pitfall: Do not equate the presence of ventricular pacing with protection against ventricular fibrillation. Resynchronisation and defibrillation address different problems and require separate treatment decisions.
Medtronic Cardiac Pacing — indications, safety, and warnings · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
2.How does the pacing mode code describe device behaviour?
The first three positions of the standard pacing code identify the chamber paced, chamber sensed and response to sensing. A denotes atrium, V ventricle and D both chambers; response codes include inhibition, triggering or both. An R in the fourth position indicates rate modulation. Thus DDDR describes dual-chamber pacing and sensing with dual responses and rate modulation. Read the code alongside programmed timing because the mode name alone does not specify actual pacing burden.
Apply it
During clinic review, a patient in sinus rhythm has a DDDR device but almost entirely intrinsic ventricular conduction. Explain why the mode permits ventricular pacing without proving that ventricular pacing occurs on every cycle.
Common pitfall: The R denotes rate modulation, not a right-sided lead. A pacing mode describes permitted behaviour, while programmed intervals and intrinsic activity determine delivered therapy.
Pathophysiology and classification of bradyarrhythmiasnot stated; examination percentage not verified
3.When does sinus node dysfunction justify permanent pacing?
Sinus node dysfunction includes inappropriate sinus bradycardia, sinus pauses and bradycardia–tachycardia presentations. Permanent pacing generally requires symptoms attributable to the bradyarrhythmia after reversible causes are considered. A low resting rate alone does not establish clinically important disease, particularly during sleep or athletic conditioning. The discriminating evidence is a credible temporal relationship between symptoms and impaired impulse formation, including symptomatic pauses after termination of atrial tachyarrhythmia or inadequate rate increase during exertion.
Apply it
A patient reports abrupt presyncope immediately after palpitations stop. Monitoring records a prolonged sinus pause at that moment. Use the symptom–rhythm relationship to distinguish clinically significant bradycardia–tachycardia disease from an incidental low resting pulse.
Common pitfall: Do not implant solely for an asymptomatic numerical heart rate. Medication effects, sleep apnoea and physiological vagal slowing can produce bradycardia without an intrinsic pacing indication.
4.Which ECG features distinguish common forms of AV block?
Mobitz I block typically shows progressive PR prolongation before a non-conducted P wave, whereas Mobitz II shows intermittent non-conduction without preceding progressive PR prolongation. Complete AV block has independent atrial and ventricular activation. Wide QRS complexes and associated bundle-branch disease increase concern for His–Purkinje disease, but surface ECG clues do not localise every block reliably. Persistent acquired Mobitz II, high-grade or complete AV block without a reversible cause warrants pacing evaluation even without symptoms.
Apply it
An asymptomatic patient has repeated dropped QRS complexes with unchanged conducted PR intervals and established bundle-branch block. Identify a potentially dangerous conduction disorder and assess reversible causes rather than dismissing it because symptoms are absent.
Common pitfall: A lack of syncope does not make advanced acquired AV block benign. Conversely, QRS width alone cannot establish the anatomical level of every block.
5.Why is 2:1 AV block difficult to classify?
In 2:1 AV block, every other atrial impulse fails to conduct, leaving no sequence of consecutive conducted PR intervals from which to identify Wenckebach behaviour. The tracing therefore cannot automatically be labelled Mobitz I or Mobitz II. QRS morphology, associated conduction disease, exercise response and, when appropriate, electrophysiological testing help assess localisation and risk. Worsening conduction as the atrial rate increases raises concern for infranodal disease, although the whole clinical context remains essential.
Apply it
A patient with exertional dizziness has 2:1 block and a broad QRS. During supervised assessment, conduction deteriorates as sinus rate rises. Explain why this pattern strengthens concern for His–Purkinje disease and consequential pacing needs.
Common pitfall: Do not label all 2:1 block Mobitz II from the ratio alone. The ratio describes conduction frequency, not the mechanism or anatomical site.
6.Why can syncope recur despite pacing for a reflex mechanism?
Reflex syncope may combine cardioinhibition with vasodilatation. Pacing can prevent or shorten bradycardia and asystole, but it does not directly reverse a major fall in vascular resistance. Benefit therefore depends on selecting patients with a clinically important documented cardioinhibitory component, rather than treating all reflex syncope as a pacing disorder. Continued episodes after technically effective pacing may reflect hypotensive susceptibility, particularly when blood pressure falls before substantial slowing of the heart rate.
Apply it
An older patient with previously documented asystolic reflex syncope receives a pacemaker. Later presyncope occurs with a maintained paced rate but a marked blood-pressure fall. Interpret the episode as possible persistent vasodepression rather than automatic device failure.
Common pitfall: A functioning pacemaker cannot guarantee prevention of reflex syncope. Treating a normal paced rate as proof against a cardiovascular mechanism overlooks persistent vasodilatation.
Pathophysiology and mechanisms of sudden death and ventricular arrhythmianot stated; examination percentage not verified
7.How does myocardial scar sustain monomorphic ventricular tachycardia?
Fibrosis and surviving myocardial bundles create channels with slow conduction and heterogeneous refractoriness. A premature impulse can encounter unidirectional block, travel through an alternative route and re-enter tissue that has recovered excitability. Repeated activation through a relatively stable circuit often produces monomorphic ventricular tachycardia. The clinical clue is sustained regular ventricular tachycardia in structural heart disease, especially after infarction. Circuit-dependent tachycardia may be interrupted by appropriately timed pacing, which underlies antitachycardia pacing.
Apply it
A patient with an old infarct develops recurrent regular ventricular tachycardia with a consistent QRS appearance. Explain how a stable scar-related circuit can account for both the repeated morphology and successful termination by programmed ventricular pacing.
Common pitfall: A regular monomorphic rhythm does not imply harmlessness. Haemodynamic tolerance depends on ventricular function, rate and other factors, while the underlying scar remains arrhythmogenic.
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death · 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing
8.Which clues identify torsades de pointes?
Torsades de pointes is polymorphic ventricular tachycardia associated with prolonged repolarisation. Early afterdepolarisations can trigger episodes, often after pauses or a short–long–short sequence in acquired long-QT states. Review QT-prolonging medicines, potassium and magnesium disturbances, and bradycardia. Polymorphic ventricular tachycardia with a normal preceding QT suggests a different mechanism, such as acute ischaemia. The distinction matters because correcting prolonged-repolarisation triggers differs from simply applying a monomorphic-VT treatment strategy.
Apply it
A patient taking a QT-prolonging medicine develops pause-associated polymorphic ventricular tachycardia with a markedly prolonged preceding QT. Identify the repolarisation abnormality and investigate electrolyte depletion and medication exposure as immediately relevant contributors to the event.
Common pitfall: The twisting QRS appearance alone is insufficient to classify all polymorphic ventricular tachycardia as torsades. Examine the preceding QT and initiating sequence.
9.Why does an ICD not prevent every mechanism of sudden death?
An ICD treats detected ventricular tachyarrhythmias through pacing or shocks according to its capabilities and programming. Defibrillation can terminate ventricular fibrillation, but it does not correct pulseless electrical activity caused by absent mechanical output, nor does it reverse all causes of terminal pump failure. Some systems provide bradycardia pacing, but electrical stimulation still requires excitable myocardium and adequate circulation. Device benefit therefore depends on the likelihood of treatable arrhythmia relative to competing non-arrhythmic mortality.
Apply it
A patient with severe multisystem illness asks whether an ICD will prevent any future cardiac death. Explain the difference between terminating ventricular fibrillation and treating profound circulatory failure despite organised electrical activity on the monitor.
Common pitfall: Do not describe an ICD as universal protection from cardiac arrest. Successful rhythm termination and meaningful survival are related but distinct outcomes in patient selection.
Evaluation of patients with suspected or documented bradycardia or conduction system diseasenot stated; examination percentage not verified
10.How should monitoring duration match symptom frequency?
Ambulatory monitoring aims to document the rhythm during a clinically relevant event. Frequent symptoms may be captured by short continuous monitoring, whereas infrequent unexplained episodes require longer external recording or an implantable loop recorder when appropriate. A normal short recording does not exclude an intermittent arrhythmia. Choose a method whose recording period and activation features fit the event frequency, abruptness and patient's ability to trigger a recording, rather than repeatedly ordering an unsuitable short test.
Apply it
A patient has unexplained abrupt syncope every few months and an unrevealing brief Holter recording. Select a longer-term recording strategy capable of capturing spontaneous events instead of interpreting the short negative study as excluding intermittent block.
Common pitfall: Finding asymptomatic bradycardia on a recording does not automatically explain syncope. Seek event correlation and assess competing causes before assigning causation or permanent treatment.
11.Which reversible contributors should be assessed before permanent pacing?
Bradycardia may reflect intrinsic conduction disease or extrinsic suppression from medicines, electrolyte abnormalities, ischaemia, endocrine disease and sleep-disordered breathing. The evaluation combines symptom history, ECG findings, medication exposure and targeted testing. A plausible reversible contributor should be corrected when feasible, while unstable bradycardia still requires immediate support. Persistence after correction, evidence of advanced conduction disease or a necessary treatment that cannot reasonably be withdrawn changes the long-term pacing assessment.
Apply it
A patient develops symptomatic slowing after a recent increase in an AV-nodal blocking medicine. Review the indication, timing, renal function and ECG, provide support if unstable, and reassess rhythm after addressing the suspected contributor.
Common pitfall: Do not assume every medicine-associated block is fully reversible. Drugs can expose underlying His–Purkinje disease, so persistent or recurrent advanced block needs further assessment.
12.When does electrophysiological testing help in syncope with bifascicular block?
Unexplained syncope with bifascicular block raises concern for intermittent advanced His–Purkinje block. Electrophysiological testing can identify prolonged His–ventricular conduction or provoke intra-Hisian or infra-Hisian block. In the 2021 ESC pacing guideline, a baseline HV interval of at least 70 ms is a significant abnormal finding in this setting. A negative study does not reliably exclude intermittent block, so subsequent prolonged monitoring or other management depends on the remaining clinical risk.
Apply it
A patient has recurrent unexplained syncope, bifascicular block and an HV interval of 82 ms. Interpret this as evidence of significant His–Purkinje disease supporting a pacing decision rather than a reassuring incidental ECG abnormality.
Common pitfall: A negative electrophysiological study does not prove that future paroxysmal AV block is impossible. Its limited sensitivity must inform follow-up and monitoring decisions.
13.How can exercise testing clarify exertional bradycardia symptoms?
Exercise testing evaluates whether sinus rate and AV conduction respond appropriately to physiological demand. Chronotropic incompetence is an inadequate heart-rate response relative to activity, interpreted with symptoms, medications and exercise effort. Exercise can also reveal rate-dependent conduction disease. Exertional fatigue alone is nonspecific, so the key is reproducing symptoms while observing the electrical response. This distinguishes a potentially correctable rate limitation from deconditioning, pulmonary disease, ischaemia or other causes of exercise intolerance.
Apply it
A patient with normal resting sinus rhythm reports exertional exhaustion. During adequately performed exercise testing, symptoms occur with little heart-rate increase and no ischaemic changes. Assess chronotropic incompetence and medication effects before choosing rate-responsive pacing.
Common pitfall: A low achieved heart rate during prematurely terminated exercise does not establish chronotropic incompetence. Effort, limiting symptoms and rate-slowing treatment affect interpretation of the result.
Heart failure and indications for CRTnot stated; examination percentage not verified
14.Which conventional heart-failure profile most strongly supports CRT?
A well-supported conventional CRT profile is symptomatic heart failure despite optimal medical therapy, LVEF no greater than 35%, sinus rhythm, left bundle-branch block and QRS duration at least 150 ms. The broad LBBB pattern signals delayed left-ventricular activation that resynchronisation can address. Benefit varies with QRS morphology and duration; a low ejection fraction alone does not establish a conventional CRT indication. Narrow-QRS heart failure without a separate ventricular-pacing indication requires a different assessment.
Apply it
A patient remains symptomatic despite appropriate heart-failure treatment, with LVEF 28%, sinus rhythm and LBBB measuring 168 ms. Recognise a strongly supported CRT profile and separately assess whether defibrillator capability should accompany resynchronisation therapy.
Common pitfall: Do not substitute echocardiographic dyssynchrony for the established ECG selection criteria in narrow-QRS heart failure. Mechanical imaging findings alone do not establish conventional CRT benefit.
15.How does CRT improve the mechanics of a dyssynchronous ventricle?
Electrical conduction delay can cause early contraction of one ventricular region while another remains inactive or stretches, wasting work and worsening mechanical coordination. CRT changes activation timing through ventricular stimulation, aiming to improve coordinated contraction, filling and functional mitral regurgitation. Beneficial reverse remodelling develops over time rather than being guaranteed by an immediately narrower paced QRS. Effective therapy requires a suitable substrate, reliable ventricular capture and treatment of competing causes of persistent heart-failure symptoms.
Apply it
After CRT implantation, a patient's ECG narrows but severe symptoms persist. Explain why electrical change is encouraging yet insufficient, and assess effective capture, ventricular function, mitral regurgitation and ongoing heart-failure treatment before declaring therapeutic success.
Common pitfall: An implanted CRT system is not proof of effective resynchronisation. Electrical capture, arrhythmia burden, lead location and the underlying myocardial substrate can all affect benefit.
16.Why can substantial right-ventricular pacing impair ventricular function?
Conventional right-ventricular pacing can activate the ventricles asynchronously, producing a contraction pattern resembling conduction delay. In susceptible patients, sustained exposure contributes to adverse remodelling and pacing-induced cardiomyopathy. The 2023 physiologic-pacing guideline treats anticipated or actual ventricular pacing around 20–40% or more as substantial for surveillance and preventive planning. Risk depends on baseline ventricular function and other factors. Periodic ventricular-function assessment helps identify deterioration before assuming that new symptoms are unrelated to pacing.
Apply it
A patient with previously preserved LVEF develops dyspnoea after years of nearly continuous right-ventricular pacing. Reassess ventricular function and alternative causes, then consider whether pacing-associated dyssynchrony should alter the pacing strategy or prompt an upgrade.
Common pitfall: A high pacing percentage alone does not diagnose pacing-induced cardiomyopathy. Demonstrate ventricular deterioration and assess ischaemia, valve disease and other plausible causes of dysfunction.
Evaluation of patients for ICD therapynot stated; examination percentage not verified
17.When does a survived ventricular arrhythmia support secondary-prevention ICD therapy?
Secondary-prevention ICD assessment follows survived ventricular fibrillation or sustained ventricular tachycardia in an appropriate clinical setting. The critical questions are whether the event had a completely reversible cause and whether meaningful survival beyond one year is expected. A preserved ejection fraction does not negate a qualifying secondary-prevention indication. Review ischaemia, electrolytes, drugs, structural disease and the circumstances of the event; an ICD addresses recurrence risk after the acute episode has been treated.
Apply it
A patient survives ventricular fibrillation, has no acute ischaemia or correctable metabolic trigger, and has good functional status despite LVEF 48%. Assess secondary-prevention ICD therapy rather than excluding the patient through a primary-prevention ejection-fraction threshold.
Common pitfall: Do not apply primary-prevention LVEF cutoffs to every survivor of ventricular fibrillation. Conversely, correctable triggers and competing prognosis must be evaluated before committing to implantation.
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline — official slide set
18.Why do primary-prevention ICD decisions require timing and reassessment?
Primary prevention treats risk before a qualifying sustained ventricular arrhythmia occurs. In ischaemic heart disease, the cited 2017 AHA/ACC/HRS guideline includes waiting at least 40 days after myocardial infarction and at least 90 days after revascularisation for relevant LVEF-based indications. Ventricular function and symptoms are reassessed on appropriate medical therapy because recovery may change eligibility. These are US guideline criteria, not EHRA examination rules, and they should not be indiscriminately transferred to every cardiomyopathy.
Apply it
A patient without sustained ventricular arrhythmia has LVEF 30% two weeks after infarction and recent revascularisation. Optimise treatment and plan reassessment rather than treating the early measurement as an automatic indication for immediate permanent primary-prevention ICD implantation.
Common pitfall: A waiting period used for LVEF-based primary prevention must not automatically delay a separate secondary-prevention indication. Establish which clinical pathway applies before using timing criteria.
19.How does imaging refine evaluation before ICD therapy?
Echocardiography establishes ventricular function, chamber size and important structural abnormalities. Cardiac magnetic resonance can clarify scar distribution and suggest specific cardiomyopathic or inflammatory substrates when clinically appropriate. These findings connect an arrhythmia to its underlying disease and may affect risk assessment, family evaluation or additional treatment. Imaging should answer a defined diagnostic question; a normal echocardiogram does not exclude primary electrical disease, and a scar finding alone is not a universal ICD indication.
Apply it
A patient has unexplained sustained ventricular tachycardia despite only mild abnormalities on echocardiography. Consider tissue-characterising imaging to investigate an occult substrate, then integrate the result with arrhythmia history, ventricular function and disease-specific management rather than using imaging alone.
Common pitfall: Do not assume normal chamber dimensions exclude inherited arrhythmic risk. Electrical syndromes can cause dangerous ventricular arrhythmias without the structural abnormalities sought on routine echocardiography.
Evaluation of patients considered for CRTnot stated; examination percentage not verified
20.Why must effective CRT capture be checked in atrial fibrillation?
Rapid or irregular intrinsic AV conduction can compete with CRT pacing in atrial fibrillation. Device counters may record delivered ventricular stimuli even when fusion or pseudofusion prevents fully effective resynchronisation. Assess ECGs, electrograms and clinical response rather than relying solely on a nominal pacing percentage. The 2021 ESC guideline supports considering AV-junction ablation when conducted AF prevents adequate biventricular capture, commonly below 90–95%, after evaluating other causes such as frequent ventricular ectopy.
Apply it
A CRT recipient with permanent AF has persistent symptoms and an apparently high pacing counter, but ECGs show frequent conducted and fused beats. Investigate actual effective capture and rate control before accepting the counter as evidence of adequate therapy.
Common pitfall: A high device-reported pacing percentage may overstate effective resynchronisation. AV-junction ablation also will not correct lost capture caused by a failing lead or ventricular ectopy.
21.How should CRT-P and CRT-D be compared for an individual patient?
CRT-P and CRT-D both provide resynchronisation, while CRT-D adds ventricular tachyarrhythmia detection and defibrillator treatment. The additional function should follow a separate ICD benefit assessment, considering prior arrhythmia, underlying disease, competing mortality, procedural burden and patient preferences. A CRT indication does not automatically settle the defibrillator decision. Explain possible shocks, generator changes and device complications alongside expected benefits so the selected system matches both clinical risk and the patient's treatment goals.
Apply it
An older patient with a clear CRT indication has substantial comorbidity and is concerned about shocks. Discuss the incremental purpose and burdens of defibrillator therapy rather than presenting CRT-D as an inseparable component of any resynchronisation procedure.
Common pitfall: Do not frame CRT-P as absence of heart-failure treatment. It delivers resynchronisation; the additional question is whether defibrillator therapy offers sufficient individual benefit.
2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure · Medtronic Cardiac Pacing — indications, safety, and warnings
22.When should an existing pacing system be evaluated for a CRT upgrade?
An existing pacemaker or ICD recipient who develops symptomatic heart failure and reduced ventricular function during substantial right-ventricular pacing should be assessed for an upgrade strategy. Establish pacing burden, paced QRS characteristics, ventricular-function trajectory and competing explanations for deterioration. The potential benefit must be weighed against an additional procedure, venous access limitations and lead-related risks. Upgrade evaluation therefore combines evidence that pacing contributes to dysfunction with the feasibility and goals of a revised system.
Apply it
A patient with complete AV block, nearly continuous right-ventricular pacing and newly reduced LVEF remains symptomatic on appropriate therapy. Review earlier imaging, exclude alternative causes and assess venous access and existing leads while considering resynchronisation or physiologic pacing.
Common pitfall: Do not recommend an upgrade from symptoms alone. Confirm the ventricular-function change, delivered pacing burden and technical feasibility before attributing deterioration to pacing-associated dyssynchrony.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy — Belgian Heart Rhythm Association PDF · 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
Indications for pacing in specific conditionsnot stated; examination percentage not verified
23.Which post-TAVI conduction findings establish a pacing indication, and which require further investigation?
TAVI can injure or compress the nearby His–Purkinje system. The 2021 ESC guideline recommends permanent pacing for complete or high-grade AV block persisting for 24–48 hours after TAVI and for new alternating bundle-branch block. New LBBB alone does not establish the same indication. For new LBBB with QRS >150 ms or PR >240 ms, ambulatory ECG monitoring or electrophysiological study should be considered when conduction intervals remain stable without further prolongation during more than 48 hours of observation. These stable findings must be distinguished from ongoing PR or QRS progression, recurrent advanced block or haemodynamic instability, which require continued inpatient monitoring and appropriate pacing support.
Apply it
On day three after TAVI, a patient has new LBBB, QRS 160 ms and PR 250 ms, with no further interval prolongation during more than 48 hours of observation. These findings support ambulatory monitoring or EPS rather than automatic pacemaker implantation. In contrast, complete AV block persisting through 48 hours supports permanent pacing. New alternating right and left bundle-branch block also establishes a pacing indication.
Common pitfall: Do not apply the stable-LBBB pathway while conduction is still deteriorating. A progressively lengthening PR interval or widening QRS signals evolving injury. Conversely, exceeding the stable-LBBB investigation thresholds does not itself mean that persistent high-grade AV block has been demonstrated.
24.Why can AV block during acute myocardial infarction resolve?
Acute infarction can impair conduction through ischaemia, oedema or autonomic effects. Inferior-infarction-associated AV nodal block may recover with treatment and reperfusion, whereas extensive anterior injury with infranodal block often signals more severe conduction-system damage. Temporary support is determined by haemodynamic and electrical instability. Permanent pacing is assessed after considering recovery and persistence, rather than using the presence of any acute block as proof of an irreversible long-term pacing requirement.
Apply it
A patient develops symptomatic AV block during an inferior infarction and needs temporary support. After reperfusion, stable AV conduction returns. Reassess the need for permanent pacing from the subsequent course instead of assuming that temporary pacing mandates implantation.
Common pitfall: Temporary pacing is a bridge for instability, not a permanent-device indication by itself. Infarct territory, block location and persistence help determine the likelihood of recovery.
25.How should replacement pacing and infection clearance be managed after extraction of an infected system?
After complete infected-system removal, reassess the continuing pacing indication and pacing dependence. The [2023 ESC endocarditis guideline](https://academic.oup.com/eurheartj/article/44/39/3948/7243107?login=true) specifies that reimplantation should await resolution of infection signs and negative blood cultures for at least 72 hours after extraction when vegetations and residual 'ghosts' are absent, or two weeks of negative blood cultures when vegetations were visualized. The AHA infection statement suggests at least three days of negative cultures before reimplantation, extending to a 14-day interval for valvular infective endocarditis. These criteria have different triggers: the ESC vegetation criterion is not restricted to valvular endocarditis. Individualize timing through multidisciplinary assessment of microbiology, imaging, infection clearance and pacing needs. Implant any necessary replacement at a different site or select an appropriate alternative system. A pacing-dependent patient may require an active-fixation transvenous lead connected to an externalized pulse generator as a bridge.
Apply it
A pacing-dependent patient undergoes complete extraction for bacteraemia with a lead vegetation but no valve vegetation. Reliable temporary pacing supports the patient while infection is treated. Even if infection signs resolve and cultures remain negative for 72 hours, the ESC pathway calls for two weeks of negative cultures because a vegetation was visualized. By contrast, an otherwise comparable patient without vegetations or residual ghosts may meet the culture criterion after at least 72 hours. Persistent bacteraemia requires further investigation and continued treatment.
Common pitfall: Do not equate elapsed time after extraction with sustained negative blood cultures. The absence of valvular endocarditis does not remove the ESC two-week requirement when a lead vegetation was visualized. Residual ghosts also prevent automatic use of the uncomplicated 72-hour pathway. Reimplantation timing and antibiotic treatment duration are separate decisions; appropriately timed replacement does not necessarily mean antimicrobial treatment is complete.
EHRA International Consensus Document on Prevention, Diagnosis, and Treatment of CIED Infections · Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association
Types and modes of pacing/defibrillator therapiesnot stated; examination percentage not verified
26.Which rhythm features guide selection between dual-chamber and ventricular pacing?
Dual-chamber pacing can preserve AV coordination in patients with useful atrial activity and an appropriate pacing indication. In permanent atrial fibrillation, atrial tracking cannot restore organised atrial contribution, so ventricular pacing strategies are usually more relevant. Device choice also considers expected ventricular pacing, ventricular function, procedural burden and patient goals. Minimising unnecessary right-ventricular pacing can be valuable when intrinsic conduction is reliable, but algorithms must not permit symptomatic pauses or unacceptable AV delays.
Apply it
Two patients have symptomatic slow ventricular rates: one has sinus rhythm with complete AV block, and the other permanent AF. Explain why the first may benefit from atrial tracking while the second lacks organised atrial activity to track.
Common pitfall: More chambers do not guarantee better treatment. An atrial lead adds procedural and lead-related burden when its sensing or pacing functions offer no meaningful patient benefit.
27.How does rate-responsive pacing differ from atrial tracking?
Atrial tracking allows sensed atrial activity to influence ventricular timing up to programmed limits. Rate-responsive pacing uses a sensor to increase pacing rate when intrinsic rate response is insufficient. The two functions address different physiological problems and can coexist in the same device. Sensor settings require correlation with activity and symptoms because an overly aggressive response can produce inappropriate rapid pacing, while an inadequate response can leave the patient limited during exertion.
Apply it
A patient with sinus node dysfunction remains breathless on walking despite reliable capture and a suitable resting rate. Assess activity-related rate response and sensor settings rather than increasing the ventricular output amplitude as treatment for exercise intolerance.
Common pitfall: Increasing the resting lower rate does not necessarily restore an appropriate exercise response. Establish whether symptoms reflect chronotropic limitation before changing sensor or timing settings.
28.What physiological target distinguishes conduction system pacing?
Conduction system pacing seeks to recruit the native His–Purkinje network rather than relying solely on myocardial activation from a conventional right-ventricular site. His-bundle pacing and left bundle-branch area pacing are major approaches. Physiological benefit depends on the achieved activation pattern and capture mechanism, not simply placing a lead near the septum. Assessment includes paced ECG characteristics and pacing manoeuvres, with follow-up of thresholds, ventricular function and reliable delivery of the intended therapy.
Apply it
A patient expected to require frequent ventricular pacing is considered for conduction system pacing. Explain that the objective is coordinated activation through the native conduction network and that septal lead location alone does not prove successful conduction-system recruitment.
Common pitfall: Do not equate every narrow paced QRS or every septal lead with confirmed conduction-system capture. Electrical evidence and technique-specific assessment determine the actual activation mechanism.
2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure · ESC announcement of the 2025 conduction system pacing consensus
29.When can leadless pacing offer a useful alternative?
Leadless pacing avoids a conventional subcutaneous generator pocket and transvenous lead connecting that pocket to the heart. It can be useful when venous access is limited or pocket and lead complications are especially concerning, provided the selected system meets the patient's pacing needs. Capabilities differ across models, so atrial support, AV coordination and future therapy requirements must be assessed explicitly. Avoiding a pocket does not eliminate intracardiac procedural risks or end-of-service planning.
Apply it
A patient with permanent AF, symptomatic bradycardia and difficult upper-body venous access needs pacing. Compare a suitable leadless option with conventional alternatives, considering access, perforation risk, expected pacing requirements and management when the device reaches end of service.
Common pitfall: Do not assume all leadless systems provide the same chamber support or eliminate all infection and procedural risks. Match the specific system's functions to the indication.
ICDsnot stated; examination percentage not verified
30.How do pacing requirements influence ICD system selection?
A transvenous ICD can provide intracardiac sensing, shocks and, when configured appropriately, bradycardia pacing and antitachycardia pacing. A conventional subcutaneous ICD avoids an intravascular defibrillation lead but does not provide chronic bradycardia pacing, CRT or conventional ATP. These differences make anticipated pacing requirements central to selection. The curriculum also includes extravascular ICDs; their capabilities must be assessed by the specific system rather than inferred from the broad non-transvenous label.
Apply it
A patient needs defibrillator protection and has recurrent monomorphic VT likely to benefit from ATP, together with established pacing needs. Explain why a conventional standalone subcutaneous ICD would not supply all the required treatment functions.
Common pitfall: Avoid choosing solely on the absence of a transvenous lead. A system that omits required pacing functions may create the need for additional hardware or another procedure.
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
31.When can defibrillation testing be omitted during ICD implantation?
The cited ICD programming consensus allows omission of routine defibrillation efficacy testing during selected initial left-pectoral transvenous ICD implants when the right-ventricular lead is well positioned and sensing, pacing and impedance measurements are appropriate. This is a defined context, not a universal rule for all systems or implant sites. Testing decisions differ for subcutaneous systems, right-sided implants and unusual configurations. The decision balances verification of defibrillation efficacy against the risks of induced ventricular fibrillation and anaesthesia.
Apply it
A standard initial left-pectoral transvenous ICD implant has a satisfactory lead position and normal electrical measurements. Recognise that omission of defibrillation testing may be reasonable, while explaining why a right-sided or unusual configuration needs separate consideration.
Common pitfall: Normal pacing capture does not itself prove successful defibrillation. The justification for omitting testing comes from evidence in selected implant settings, not equivalence of those functions.
2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing
Pacemaker and ICD systemsnot stated; examination percentage not verified
32.How do voltage, impedance and pulse duration determine pacing charge?
For a simplified constant-voltage pulse into a resistive load, current equals voltage divided by resistance, and delivered charge equals current multiplied by pulse duration. At 2.5 V across 500 ohms, current is 5 mA; over 0.4 ms, charge is 2 microcoulombs. Real electrode–tissue behaviour is more complex, but these relationships explain why output and pulse width affect energy use. Approximate pulse energy is voltage squared multiplied by duration and divided by resistance.
Apply it
Compare two otherwise identical constant-voltage settings across 500 ohms: 2.5 V at 0.4 ms and 5 V at 0.4 ms. The second doubles current and charge but approximately quadruples pulse energy under the simplified resistive model.
Common pitfall: Do not confuse charge with energy or equate voltage directly with current. Pulse duration and circuit impedance must be included in the relevant calculation.
NIST SP 330 — Section 2: The International System of Units · Boston Scientific Bradycardia Pacemaker Reference Guide
33.How should capture threshold be interpreted and programmed?
Capture threshold is the minimum output that consistently depolarises myocardium at a specified pulse width and testing condition. It is not a single voltage independent of duration: the strength–duration relationship means a longer pulse may capture at lower amplitude. Confirm capture on the surface ECG or appropriate electrograms and provide a suitable safety margin or validated automatic capture management. Unexpected threshold elevation requires assessment of lead position, tissue changes, medicines and metabolic abnormalities.
Apply it
A ventricular threshold is satisfactory at one pulse width but capture is lost after shortening that duration without changing amplitude. Recheck the strength–duration relationship and restore a reliable margin rather than concluding that the generator has necessarily failed.
Common pitfall: A visible pacing spike does not prove myocardial capture. Verify the ensuing depolarisation, especially when dependence, a changing threshold or a recent implant increases clinical risk.
34.Why does a lower programmed sensing value mean greater sensitivity?
A programmed sensing threshold in millivolts represents the minimum signal amplitude the device will recognise under the applicable sensing rules. Lowering that numerical threshold permits smaller signals to be detected, increasing sensitivity. This can correct undersensing but may increase susceptibility to noise or far-field signals. Raising the threshold reduces sensitivity and can reduce oversensing while risking missed intrinsic activity. Interpret the setting with signal amplitude, morphology, timing windows and device-specific automatic sensing behaviour.
Apply it
A device misses intrinsic R waves whose amplitude is below its fixed programmed sensing threshold. Lowering the millivolt value may restore detection, but first inspect electrograms and lead integrity to ensure that the apparent solution does not introduce noise oversensing.
Common pitfall: Do not increase the millivolt number when the goal is greater sensitivity. Also avoid treating every sensing problem as a programming error without checking the lead.
35.How do blanking and refractory periods affect device timing?
Blanking prevents selected signals from being sensed during a protected interval, helping avoid detection of pacing artefacts or cross-chamber signals. A refractory interval can allow event recognition or annotation while preventing the event from triggering the usual timing response, depending on the system. Post-ventricular atrial refractory period prevents inappropriate tracking of some retrograde atrial activity. Longer protection can reduce oversensing or PMT, but it can also limit atrial tracking at faster physiological rates.
Apply it
A dual-chamber recipient develops exertional symptoms when sinus rate rises. Review AV delay, post-ventricular atrial refractoriness and upper-rate behaviour before assuming that the sinus node is failing or that the ventricular lead has lost capture.
Common pitfall: Blanking and refractoriness are not interchangeable terms. Extending either without considering timing consequences can solve one sensing problem while creating missed tracking or exercise-related limitation.
36.How does pacemaker-mediated tachycardia complete its circuit?
Classic pacemaker-mediated tachycardia requires a tracking mode and retrograde ventriculoatrial conduction. A ventricular event conducts back to the atrium; the device senses that atrial event outside the refractory period and delivers another ventricular pace after the AV delay. The device forms the antegrade limb of the loop. Electrograms show repeated ventricular pacing followed by retrograde atrial sensing. Appropriate PVARP adjustment or a device PMT-termination algorithm can interrupt tracking, with attention to exercise-related upper-rate effects.
Apply it
After a ventricular premature beat, a patient develops regular tachycardia near the upper tracking rate. Electrograms show ventricular pacing followed by atrial sensing at a consistent VA interval. Identify a retrograde tracking loop and assess the programmed PMT safeguards.
Common pitfall: Do not diagnose sinus tachycardia solely because every ventricular pace follows an atrial marker. Determine whether atrial activation precedes the ventricular event physiologically or follows it retrogradely.
Boston Scientific Bradycardia Pacemaker Physician's Technical Manual · Boston Scientific Bradycardia Pacemaker Reference Guide
37.How does repetitive non-reentrant ventriculoatrial synchrony differ from classic pacemaker-mediated tachycardia?
Repetitive non-reentrant ventriculoatrial synchrony requires retrograde VA conduction. A ventricular paced beat activates the atrium retrogradely during the post-ventricular atrial refractory period, so that atrial event does not initiate a tracked AV delay. The next scheduled atrial stimulus arrives while the atrial myocardium remains refractory and fails to capture: functional atrial noncapture. Nevertheless, the atrial pacing stimulus starts the programmed AV delay, after which another ventricular stimulus repeats the sequence. In classic PMT, the retrograde atrial event is sensed outside PVARP and tracked to produce ventricular pacing. Long AV delays, long PVARP and short pacing cycle lengths favour RNRVAS; initial loss of atrial capture can trigger it.
Apply it
During an atrial threshold test, loss of capture is followed by ventricular pacing, a retrograde atrial event marked refractory, another noncapturing atrial stimulus and ventricular pacing after the AV delay. This sequence supports RNRVAS. Management can include restoring an adequate atrial capture margin, reducing an unnecessarily high paced rate or shortening a long paced AV delay, according to the patient's conduction and pacing requirements.
Common pitfall: Device refractoriness and myocardial refractoriness are different: PVARP prevents tracking, whereas refractory atrial tissue explains functional noncapture. Lengthening PVARP to treat every VA-associated rhythm can favour RNRVAS. Stored atrial high-rate detections also require electrogram review because this sequence can mimic atrial tachyarrhythmia.
Boston Scientific Bradycardia Pacemaker Reference Guide · Potential triggering of repetitive nonreentrant ventriculoatrial synchrony by loss of atrial capture - PMC
38.How do ICD detection settings and ATP reduce unnecessary shocks?
ICD therapy depends on rate zones, detection duration, rhythm discrimination and the programmed treatment sequence. Longer detection can allow nonsustained rhythms to terminate, while appropriate discriminators reduce treatment of supraventricular tachycardia. ATP can interrupt suitable re-entrant monomorphic VT without a shock, but it may fail or accelerate tachycardia. Programming must retain coverage of the patient's documented clinical VT and provide appropriate backup therapy. Numerical settings and algorithms are device-specific and require individual interpretation.
Apply it
A patient receives shocks for brief self-terminating tachycardias and also has documented slower sustained VT. Review detection duration, discriminators and ATP while ensuring that revised zones still recognise the known clinical ventricular rhythm rather than merely raising every rate threshold.
Common pitfall: Shock reduction does not justify programming away clinically important VT. Discriminators, detection delays and ATP each have boundaries and must be matched to the arrhythmia history.
2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing · 2019 HRS/EHRA/APHRS/LAHRS Focused Update to the ICD Programming and Testing Consensus
39.Which findings help distinguish conductor failure from insulation damage?
A conductor fracture may produce intermittent high impedance and nonphysiological noise, while an insulation breach may create a low-impedance current pathway. These are useful patterns rather than infallible rules: intermittent defects can generate noise before routine impedance measurements become abnormal. Review trends, stored electrograms, provocative manoeuvres when appropriate and imaging. Lead noise can inhibit necessary pacing or trigger inappropriate ICD therapy, so immediate clinical risk depends on pacing dependence and the therapies potentially affected.
Apply it
A pacing-dependent patient develops pauses with bursts of high-frequency nonphysiological ventricular signals. Even if the latest impedance value is normal, investigate intermittent lead failure and provide appropriate protection against pacing inhibition while the cause is clarified.
Common pitfall: A normal single impedance measurement does not exclude lead failure. Conversely, an isolated abnormal value requires correlation with trends, electrograms and clinical context before deciding on intervention.
Boston Scientific Bradycardia Pacemaker Reference Guide · 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing
Follow-upnot stated; examination percentage not verified
40.What makes a device follow-up assessment clinically complete?
A systematic follow-up links symptoms and examination with battery status, lead measurements, sensing and capture, pacing burden, stored arrhythmias and programmed therapy. Trends often reveal more than isolated values. Review medicines and changes in the patient's condition because rate control, electrolytes and heart-failure progression can alter device performance or treatment needs. The aim is to confirm that the system delivers appropriate therapy for the current patient, rather than merely documenting that interrogation communicates successfully.
Apply it
A routine interrogation reports normal battery and impedance, but the patient describes new exertional dizziness. Examine stored events, rate response, upper-rate behaviour and capture under relevant conditions instead of closing the visit after checking the summary measurements.
Common pitfall: Normal headline measurements do not establish symptom resolution or appropriate programming. A device can function exactly as programmed while its settings no longer fit the patient's needs.
2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic · Boston Scientific Bradycardia Pacemaker Reference Guide
41.Why does remote monitoring require a defined clinical workflow?
Remote monitoring can identify arrhythmias, lead abnormalities and battery changes earlier, but benefit depends on connectivity, meaningful alert settings and timely review by a responsible team. It is not continuous emergency surveillance and does not replace urgent assessment for serious symptoms. Patients need clear instructions about transmission failures, clinic response expectations and emergency care. The clinic must distinguish high-priority actionable alerts from routine information and document its response rather than assuming transmission itself completes clinical management.
Apply it
A patient sends a routine remote transmission while experiencing ongoing syncope and chest discomfort. Explain that transmission does not provide emergency evaluation, direct immediate clinical assessment, and separately confirm that the device clinic receives and reviews the relevant data.
Common pitfall: Do not promise immediate intervention whenever a device transmits. Connectivity gaps, clinic hours and alert processing mean remote monitoring cannot substitute for emergency services during acute symptoms.
42.How should persistent symptoms after CRT be investigated?
Persistent symptoms after CRT require a structured search for remediable causes. Confirm ventricular capture and effective resynchronisation, then assess atrial fibrillation, ventricular ectopy, lead position, programmed timing and loss of left-ventricular capture. Reassess ventricular function, valve disease, myocardial substrate and heart-failure therapy. No single device measurement establishes response or nonresponse. A patient may have limited reverse remodelling despite technically effective delivery, while another may improve after correcting an avoidable interruption of therapy.
Apply it
A CRT recipient initially improves but later deteriorates. Interrogation reveals increasing ventricular ectopy and reduced effective pacing. Address the competing rhythm and reassess delivery rather than immediately replacing the left-ventricular lead or labelling the therapy ineffective.
Common pitfall: Repeated timing optimisation cannot correct every cause of persistent heart failure. Lead capture, arrhythmias, myocardial disease and noncardiac illness must be assessed before attributing symptoms to AV timing.
Operating room considerationsnot stated; examination percentage not verified
43.What must the implant team confirm before starting a procedure?
A team brief verifies patient identity, indication, consent, planned system and side, allergies, infection status, anticoagulation plan and required equipment. It also establishes roles and rescue arrangements for bradycardia, defibrillation, airway problems and tamponade. External rescue capability remains necessary even when an implanted device is present or planned. The brief should surface disagreements or missing resources before sedation and incision, when correcting an error is easier and the patient can still participate.
Apply it
Before an ICD upgrade, the team discovers that the planned lead connector is incompatible with the available generator. Resolve the equipment mismatch during the brief and confirm rescue pacing and defibrillation arrangements before sedation or pocket opening.
Common pitfall: A completed consent form does not replace a shared procedural plan. Equipment compatibility, dependence and emergency responsibilities can remain unresolved despite correct documentation of consent.
EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
44.How can fluoroscopic exposure be reduced during implantation?
Radiation protection combines minimising exposure time, increasing distance when feasible and using appropriate shielding. Collimation, suitable pulse rates, avoiding unnecessary magnification and planning useful projections reduce patient and operator dose. Staff exposure largely arises from scatter, so shielding and positioning matter even when the operator is outside the direct beam. Dose awareness must coexist with adequate visualisation: reducing exposure should not compromise safe lead placement or the recognition of a developing procedural complication.
Apply it
During a difficult lead placement, an operator repeatedly uses broad-field high-magnification fluoroscopy without changing the view. Improve collimation, pulse settings and projection planning, while preserving the images needed to confirm position and avoid repeated ineffective manoeuvres.
Common pitfall: Protective clothing does not eliminate scatter exposure. Conversely, reducing fluoroscopy so aggressively that lead position becomes uncertain can undermine procedural safety and cause avoidable repeat imaging.
CIED implant techniquenot stated; examination percentage not verified
45.Why are cephalic or axillary access often preferred to intrathoracic subclavian puncture?
Cephalic cutdown and appropriately performed extrathoracic axillary access avoid the intrathoracic needle trajectory associated with pneumothorax during subclavian puncture. They also reduce exposure of leads to costoclavicular compression that can contribute to long-term lead damage. Ultrasound can help identify the axillary vein and surrounding anatomy. Access selection still depends on anatomy, venous patency, operator expertise and the planned system; a preferred approach must remain technically safe for the individual patient.
Apply it
A patient with severe pulmonary disease needs a transvenous pacemaker. Consider cephalic or ultrasound-guided extrathoracic axillary access to reduce pleural injury risk, while reviewing venous anatomy and retaining a clear alternative if the preferred route is unsuitable.
Common pitfall: Do not assume every puncture labelled subclavian is extrathoracic or equally safe. The actual needle path and lead course determine pleural and compression-related risks.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy — Belgian Heart Rhythm Association PDF · EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators
46.How should fluoroscopic views and electrical measurements guide lead placement?
Lead placement requires anatomical and electrical confirmation. Multiple fluoroscopic projections help distinguish true chamber location and lead orientation, while sensing, capture threshold and impedance assess the electrode–tissue interface. Appropriate slack must accommodate cardiac motion without promoting instability or excessive loops. A satisfactory electrical measurement cannot compensate for uncertain anatomical position, and an attractive fluoroscopic image does not prove reliable capture. Reassess after fixation and before closure because manipulation or generator connection can reveal instability.
Apply it
A ventricular lead has a low capture threshold in one projection, but its anatomical position remains uncertain. Obtain additional views and verify sensing, impedance and mechanical stability before accepting the lead solely because the threshold appears favourable.
Common pitfall: Good acute electrical values do not exclude malposition or future dislodgement. Confirm anatomy and stability instead of using a single threshold measurement as the entire acceptance test.
47.Why should extracardiac stimulation be tested before implant closure?
A pacing stimulus can activate nearby extracardiac structures, producing diaphragmatic or chest-wall contraction. Left-ventricular coronary venous pacing can stimulate the phrenic nerve because of anatomical proximity. Testing across relevant outputs and available vectors helps establish a reliable myocardial capture margin without unacceptable extracardiac stimulation. A quadripolar lead may offer alternative vectors, but programming cannot solve every anatomical limitation. Testing before closure can prevent a later reintervention when output needs or body position change.
Apply it
A coronary venous lead captures the left ventricle but causes diaphragmatic contraction near the required output. Compare available pacing vectors and capture margins, and reconsider lead position if reliable resynchronisation cannot be delivered without troublesome extracardiac stimulation.
Common pitfall: Do not simply lower output below a dependable myocardial safety margin to suppress diaphragmatic symptoms. Avoiding extracardiac stimulation is useful only if ventricular capture remains reliable.
EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators · 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
Complications: identification and managementnot stated; examination percentage not verified
48.Which post-implant findings should raise concern for perforation and tamponade?
New chest pain, dyspnoea, hypotension or unexplained deterioration after lead implantation should prompt assessment for perforation and pericardial effusion. Capture or sensing changes may occur, but normal electrical parameters do not exclude perforation. Urgent echocardiography assesses effusion and haemodynamic consequences, while resuscitation and specialist management proceed according to stability. Tamponade is an obstructive circulatory emergency; the immediate issue is restoring haemodynamics and controlling the cause, not completing a routine interrogation.
Apply it
Soon after ventricular lead implantation, a patient becomes hypotensive with chest discomfort despite apparently normal lead impedance. Obtain urgent haemodynamic assessment and echocardiography for tamponade while mobilising the team and equipment required for emergency treatment.
Common pitfall: Do not use normal sensing or capture to dismiss perforation. Clinical deterioration after implantation demands investigation even when device measurements remain within their previous ranges.
49.How should acute breathlessness after venous access be evaluated?
Pneumothorax is an important cause of breathlessness or pleuritic pain after thoracic venous puncture. Assess oxygenation, respiratory and haemodynamic status, and obtain appropriate bedside imaging or chest radiography according to stability. Severe instability with clinical tension physiology requires immediate emergency management rather than waiting for routine imaging. Other possibilities include tamponade, haemothorax, pulmonary oedema and sedation-related hypoventilation. The access route and timing help prioritise the differential but do not replace examination.
Apply it
After difficult intrathoracic venous access, a patient develops unilateral pleuritic pain, falling oxygen saturation and reduced breath sounds. Evaluate urgently for pneumothorax and determine whether haemodynamic compromise requires immediate treatment before confirmatory routine imaging is available.
Common pitfall: Do not attribute new post-procedural dyspnoea automatically to anxiety or sedation. Pleural injury and haemodynamic complications require active assessment, especially after difficult access.
50.Why does exposed CIED hardware indicate infection even without fever?
Generator or lead exposure through the skin establishes pocket involvement because the hardware communicates with the external environment and is considered infected. Absence of fever, negative blood cultures or minimal surrounding inflammation does not make exposed hardware sterile. Management generally requires complete system removal with antimicrobial treatment guided by the infection assessment. Simply closing the skin or changing the generator leaves potentially colonised material behind and does not provide reliable source control.
Apply it
A patient has a small painless pocket erosion with visible generator metal, normal temperature and negative blood cultures. Recognise definite local device infection and arrange specialist complete-system management instead of offering simple wound closure or observation.
Common pitfall: Do not use negative blood cultures to exclude pocket infection. They address bloodstream involvement and cannot establish that exposed generator or lead material is uninfected.
EHRA International Consensus Document on Prevention, Diagnosis, and Treatment of CIED Infections · Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association
Special considerations to minimize complicationsnot stated; examination percentage not verified
51.How should warfarin be managed around device surgery in patients at high thromboembolic risk?
For appropriate patients undergoing pacemaker or ICD implantation or generator replacement, uninterrupted therapeutic warfarin is preferred to interruption with heparin bridging when thromboembolic risk is sufficiently high. Bridging increases clinically significant pocket haematoma, which can require further intervention and increase infection risk. Check the intended INR range and procedural plan rather than treating continuation as permission for excessive anticoagulation. This evidence does not mean every anticoagulant or every procedure follows an identical strategy.
Apply it
A patient with AF, substantial thromboembolic risk and a therapeutic INR is scheduled for generator replacement. Compare continued warfarin with interruption and heparin bridging, focusing on pocket-haematoma evidence and the patient's anticoagulation indication before finalising the plan.
Common pitfall: Heparin bridging is not automatically the safer compromise. It can increase pocket bleeding, and recommendations for warfarin should not be copied unchanged to direct oral anticoagulants.
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation — author manuscript · EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators
52.Which perioperative measures reduce CIED infection and haematoma?
Infection prevention combines appropriate pre-incision antibiotic prophylaxis, skin preparation, sterile technique, careful haemostasis and avoidance of unnecessary reintervention. Active infection or fever should trigger reassessment of an elective implant. Pocket haematoma matters because it increases subsequent infection risk; routine needle aspiration is discouraged because it can inoculate the pocket. A tense haematoma threatening skin integrity or causing major symptoms requires specialist assessment, while uncomplicated haematoma is usually managed without opening or puncturing the pocket.
Apply it
A patient develops a stable pocket haematoma without threatened skin or systemic infection. Avoid routine needle aspiration, review bleeding contributors and arrange follow-up, while identifying the changes that would require urgent reassessment or surgical management.
Common pitfall: Postoperative antibiotics cannot compensate for poor sterile technique or an avoidable haematoma. Routine aspiration may appear simple but can introduce organisms into an otherwise uninfected pocket.
EHRA International Consensus Document on Prevention, Diagnosis, and Treatment of CIED Infections · EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators
CIED extraction and lead management strategiesnot stated; examination percentage not verified
53.How should extraction and abandonment be compared for a noninfected failed lead?
A noninfected failed lead does not automatically require extraction. Compare removal with abandonment by considering patient age, anticipated future procedures, venous access, lead burden, lead dwell time and procedural risk. Extraction removes retained hardware but can cause major vascular or cardiac injury; abandonment avoids immediate extraction risk but leaves long-term hardware and access issues. Infection changes this balance because complete removal is generally required. The decision should include the patient's expected lifetime device needs.
Apply it
A young patient with a noninfected failed lead and limited venous access needs another decades-long device strategy. Discuss extraction and abandonment in terms of immediate risk, future lead burden and access rather than applying the same choice used for an older low-demand patient.
Common pitfall: Neither routine extraction nor routine abandonment fits every sterile lead failure. Do not apply an infection-driven complete-removal rule to all noninfected malfunctioning leads.
EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
54.Why does lead extraction require immediate rescue capability?
Chronic leads can become firmly adherent to veins, the superior vena cava and cardiac tissue. Separating these adhesions risks vascular tear, perforation and sudden haemodynamic collapse. Extraction therefore requires pre-procedure risk assessment, an experienced team, suitable imaging, blood availability and a clearly executable surgical rescue pathway. Lead dwell time, number and design influence complexity. Knowledge of extraction tools is insufficient without recognising that a rare catastrophic complication can require intervention within minutes.
Apply it
A patient with several long-dwell leads is referred for extraction. Assess adherence-related risk and confirm immediate rescue resources and team responsibilities before scheduling the procedure, rather than judging suitability only from whether extraction sheaths and snares are available.
Common pitfall: Describing extraction as a generator change understates its hazards. A low average complication rate does not remove the need for immediate management of major vascular injury.
EHRA International Consensus Document on Prevention, Diagnosis, and Treatment of CIED Infections · 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
Shared foundations for all heart rhythm specialistsnot stated; examination percentage not verified
55.How do automaticity, triggered activity and re-entry differ?
Automaticity arises from spontaneous impulse formation, whereas triggered activity depends on afterdepolarisations linked to preceding action potentials. Re-entry requires a pathway that allows repeated excitation after tissue recovers. These mechanisms explain different responses to pacing, cycle length and drugs. A reproducibly inducible and terminable circuit-mediated tachycardia supports re-entry, while pause-associated long-QT polymorphic tachycardia suggests early-afterdepolarisation-triggered activity. Mechanism informs treatment, but a single observed response rarely proves the entire diagnosis without supporting evidence.
Apply it
Compare a scar-associated regular VT terminated by ATP with pause-associated polymorphic VT during QT prolongation. Explain why interruption of a circulating wavefront fits the first mechanism, whereas abnormal repolarisation-related triggering better explains the second.
Common pitfall: Do not classify an arrhythmia solely because pacing changed it. Pacing can affect several mechanisms, and the substrate, initiation pattern and electrophysiological behaviour must support the inference.
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death · 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing
56.Why does conduction-system anatomy matter in device procedures?
The AV node connects atrial activation to the His bundle and branching His–Purkinje network, which rapidly distributes ventricular excitation. Proximity of this tissue to septal structures explains both opportunities for conduction system pacing and vulnerability during valve or septal procedures. Coronary sinus anatomy determines access to epicardial left-ventricular venous pacing sites. Anatomical understanding therefore supports diagnosis, procedural planning and complication recognition rather than serving only as a list of named structures to memorise.
Apply it
A patient develops new conduction disease after an aortic valve procedure. Relate the change to the nearby His–Purkinje system, and use the evolving ECG and clinical course to assess risk rather than assuming the injury is unrelated.
Common pitfall: An anatomical target does not guarantee the desired electrical result. Confirm conduction-system recruitment or reliable myocardial capture using electrical evidence rather than lead location alone.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy — Belgian Heart Rhythm Association PDF · 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
57.Which history suggests inherited electrical disease despite normal imaging?
Syncope during exertion or emotional stress, unexplained young sudden deaths in relatives and characteristic ECG abnormalities can indicate inherited electrical disease even when routine imaging is normal. Different syndromes have different triggers and ECG behaviour; for example, adrenergically associated ventricular arrhythmia suggests a different evaluation from a prolonged-QT presentation. Assessment requires careful family history, appropriate ECG and exercise evaluation, and specialist-directed testing. A normal resting ECG or structurally normal heart does not exclude every inherited syndrome.
Apply it
A young adult has exertional syncope, normal echocardiography and a relative who died suddenly during sport. Investigate an inherited arrhythmic disorder with appropriate specialist assessment rather than reassuring solely from the normal structural study.
Common pitfall: Do not equate a normal echocardiogram with low arrhythmic risk in every patient. Family history, event triggers and electrical testing can reveal disease without visible structural abnormalities.
Patient centred carenot stated; examination percentage not verified
58.How should device decisions incorporate goals and advance care planning?
Shared decisions explain the expected benefit, limitations and burdens of each device function in terms the patient can use. Defibrillator shocks, bradycardia pacing and resynchronisation are separable treatments, so goals may change without requiring every function to be stopped together. Advance care planning should address future deterioration, generator replacement and possible shock deactivation. Document preferences and the agreed clinical plan, including symptom management and who will implement programming changes when the patient's goals evolve.
Apply it
A patient with advanced terminal illness wishes to avoid painful ICD shocks but still values symptom-relieving pacing. Discuss selective deactivation of tachyarrhythmia therapies while considering continuation of pacing and CRT according to dependence, symptoms and informed preferences.
Common pitfall: Do not assume a resuscitation decision automatically specifies all device settings. Clarify each therapy with the patient and team, then document and implement the agreed plan.
2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure · 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
59.How should MRI eligibility be assessed for a patient with a CIED?
MRI assessment concerns the complete system: generator, all leads, combinations, abandoned or fractured hardware, implant circumstances and the manufacturer's conditions. An MR-conditional generator alone does not establish an MR-conditional system. Selected patients with non-MR-conditional systems can undergo scanning within an experienced protocol after risk–benefit assessment. Pre-scan interrogation, dependence-specific programming, monitoring and post-scan checks are essential. Conditional status therefore describes a tested set of conditions rather than unrestricted permission or a universal prohibition.
Apply it
A patient receives an MR-conditional replacement generator but retains older leads. Check the full system and scan requirements rather than approving MRI from the generator label alone, and consider an experienced nonconditional-device pathway when clinically justified.
Common pitfall: Do not equate non-MR-conditional with an absolute ban or MR-conditional with risk-free scanning. Complete-system assessment and an appropriate monitored protocol determine the practical decision.
2024 SCMR Expert Consensus Statement for Cardiovascular Magnetic Resonance of Patients with a CIED
60.How do magnet responses affect planning for electrosurgery?
Electrosurgical interference may be sensed as cardiac activity, inhibiting pacing or causing inappropriate ICD detection. A magnet commonly suspends ICD tachyarrhythmia therapies but usually does not make ICD bradycardia pacing asynchronous. Pacemaker magnet responses differ by device and programming. Planning therefore considers pacing dependence, operative site, current path, access to the device and verified magnet behaviour. When reprogramming is required, ensure monitoring, external rescue capability and restoration of the original therapies after the procedure.
Apply it
A pacing-dependent ICD recipient needs surgery near the generator with monopolar electrosurgery. Do not rely on a magnet alone to prevent pacing inhibition; arrange a verified pacing and tachytherapy plan with monitoring and post-procedure restoration.
Common pitfall: A magnet is not a universal asynchronous-pacing switch. Assuming that ICD shock suspension also protects a pacing-dependent patient from inhibition can leave a critical hazard unaddressed.
EHRA Consensus on Prevention and Management of Interference Due to Medical Procedures
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Distinguish symptomatic sinus node dysfunction from advanced acquired AV block, where symptoms are not always required for pacing.
- Use symptom frequency, ECG localisation clues and selected electrophysiological findings to choose the next bradycardia investigation.
- Separate conventional CRT selection, effective resynchronisation delivery and the independent decision about defibrillator capability.
- Differentiate secondary-prevention ICD assessment from LVEF-based primary prevention and its reassessment periods.
- Draw timing sequences for undersensing, oversensing, PMT and repetitive non-reentrant VA synchrony before changing programming.
- Connect implant anatomy and electrical measurements with access choice, lead stability and recognition of acute complications.
- Treat remote monitoring as a clinical service with connectivity and response responsibilities.
- Practise infection source control, anticoagulation decisions, lead-management trade-offs and dependence-specific MRI or surgical planning.
A practical preparation plan
1. Map the full syllabus
Use shared Table 3 and CIED Table 4 as a coverage ledger. Mark each subject as explainable, applicable to a case or still uncertain. Add subjects beyond these 60 concepts; do not infer examination percentages from curriculum knowledge levels.
2. Build indication contrasts
Compare paired cases: asymptomatic sinus bradycardia versus Mobitz II block, primary versus secondary ICD prevention, and narrow-QRS heart failure versus broad LBBB. State the decisive finding and the boundary that changes the decision.
3. Work through timing and signals
Draw atrial and ventricular events, AV delay and refractory intervals. Calculate simple pacing current and charge, then interpret capture, sensitivity and lead-noise examples using the applicable technical manual.
4. Rehearse procedural consequences
For each implant scenario, explain access choice, rescue readiness and post-procedure deterioration. Contrast sterile lead failure with exposed hardware and uncomplicated haematoma with threatened skin or systemic infection.
5. Use the drills diagnostically
Answer the 20 questions before reading explanations. For each error, identify whether the problem was mechanism, indication, timing or a missed discriminating cue. Revisit the cited source and use the flashcards for spaced active recall.
6. Integrate supervised clinical learning
Discuss uncertain electrograms and treatment decisions with experienced supervisors. Relate knowledge to the physician pathway's practical training and logbook requirements, and check the current programme page for administrative changes before applying.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- EHRA Certification in Cardiac Implantable Electronic Devices for Physicians (CIED)
- 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
- 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals
- ESC 365 — Doctor Laura Perrotta
- NIST SP 330 — Section 2: The International System of Units
- Boston Scientific Bradycardia Pacemaker Reference Guide
- Boston Scientific Bradycardia Pacemaker Physician's Technical Manual
- 2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline — official slide set
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
- 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
- 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy — Belgian Heart Rhythm Association PDF
- Medtronic Cardiac Pacing — indications, safety, and warnings
- 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure
- ESC announcement of the 2025 conduction system pacing consensus
- 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal ICD Programming and Testing
- 2019 HRS/EHRA/APHRS/LAHRS Focused Update to the ICD Programming and Testing Consensus
- 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic
- 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
- EHRA International Consensus Document on Prevention, Diagnosis, and Treatment of CIED Infections
- Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association
- EHRA Expert Consensus Statement and Practical Guide on Optimal Implantation Technique for Conventional Pacemakers and Implantable Cardioverter-Defibrillators
- EHRA Consensus on Prevention and Management of Interference Due to Medical Procedures
- 2024 SCMR Expert Consensus Statement for Cardiovascular Magnetic Resonance of Patients with a CIED
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation — author manuscript
- 2026 HRS Expert Consensus Statement Update on CIED Lead Management and Extraction
- Potential triggering of repetitive nonreentrant ventriculoatrial synchrony by loss of atrial capture - PMC
- 4_hrs_consensus_statement.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.